



# *Bordetella pertussis* Epidemiology and diagnostic tools in Belgium



Denis Piérard



Universitair Ziekenhuis Brussel



Vrije Universiteit Brussel



**DIAGNOSTIC TESTS**

PCR	+++	+++	+++	++	+				
Culture	+++	+++	++	+					
DFA	++	++	+	+					
Serology					+	++	++		

**COMPLICATIONS**

Apnea, bradycardia	+++	+++	++	+	+				
Seizures, encephalopathy	++	+++	++	+	+				
2° Pneumonia, atelectasis		+++	++	+					
Malnutrition, apathy			++	+++	+++	++	++	++	+

# Clinical manifestations

- Classical pertussis (mainly in unimmunized toddlers and children)
  - 3 stages, after incubation of 7 to 10 days (range 5 to 21 days)
    - Catarrhal: nondistinctive catarrhal symptoms
    - Paroxysms of cough with inspiring whoop and often post-tussive vomiting
    - Convalescent phase: , with recurrence of paroxysmal cough for up to 1 year
- Atypical pertussis
  - Infants: less inspiratory whoop but gagging, gasping, cyanosis, apnea and prolonged convalescent phase
  - Immunized children and adults: all stages foreshortened, often without paroxysms and without distinct stages

# Clinical manifestations, atypical disease in babies

## Severe and unrecognised: pertussis in UK infants

- Crowcroft et al. Arch Dis Child 2003; 88: 802-806  
Inclusion:
  - n=142 infants < 5 m, admission in PICU
  - resp failure – ALTE
  - systematically specimen collection for microbiology (incl *B pertussis*)Results:
  - 23% (n=33) pertussis confirmed (PCR, culture)
    - 33% co-infection with RSV
    - n=2 cases of fatality
- Conclusion:
  - severe pertussis is “atypical” and underdiagnosed
  - clinical diagnosis is difficult
  - RSV co-infection does not exclude pertussis and can aggravate clinical course

# Clinical manifestations, atypical disease in oldies

## A Pertussis Outbreak Associated with Social Isolation among Elderly Nuns in a Convent

Mertens et al. Clin Infect Dis 2007; 44:266-8

- Outbreak in a Dutch convent in 1992, recognized at week 10; cohort study started at week 12. **Total: 66 cases / 75 n**
- Diagnosis: PCR, culture, significant change (3-fold) in IgG ab titres at weeks 9, 13 and 60 or single titre > 100 U/ml

- Incidence rates

- 75 retired nuns (none vaccinated) IR = 60%
  - 9 with life-long career in convent IR = 100%
  - 66 with career outside convent IR = 55% P = 0,007

of which:

  - only in Dutch society IR = 74%
  - only in tropics IR = 35%
  - both IR = 17% P < 0,0001
- 24 staff members (21 vaccinated) IR = 8%

- Mortality

3/4 deaths were among nuns in age group 85-94 years

# Clinical manifestations, atypical disease in oldies

## A Pertussis Outbreak Associated with Social Isolation among Elderly Nuns in a Convent

**Table 1. Relationship between pertussis incidence, age, and duration of isolation from society among 75 nuns with ( $n = 66$ ) and nuns without ( $n = 9$ ) a career outside the convent.**

Group	Pertussis incidence			Duration of cough among nuns with pertussis		No. of deaths among nuns with pertussis
	No. with pertussis/total	Percentage	$P$ for linear trend in proportions	Median days (range)	$P$ for trend on rank	
Age group, years			.31		.20	
55–64	8/16 <sup>a</sup>	50		41 <sup>b</sup> (28–98)		1
65–74	13/21	62		67 (14–268)		0
75–84	16/27	59		51 (11–178)		0
85–94	8/11 <sup>a</sup>	73		83 <sup>b</sup> (28–236)		3
Duration of isolation from society, <sup>c</sup> years			.005		.72	
0–6	5/15	33		55 (28–173)		1
7–13	9/17	53		38 (14–268)		0
14–20	10/16	63		88 (11–178)		1
21–34	9/12	75		45 (30–236)		1
35–70	12/15	80		53 (14–159)		1

<sup>a</sup> No significant difference between the incidence of pertussis in the youngest and oldest age group ( $P = .21$ , Fisher's exact test).

<sup>b</sup> No significant difference between the median duration of cough in the youngest and oldest age group ( $P = .10$ ).

<sup>c</sup> Duration of isolation of the 9 nuns without a career outside the convent and the duration of isolation since retirement of the 66 nuns with a career outside the convent.



Discussion: waning immunity due to social isolation in women born in 1898-1936, when 100% of population experienced pertussis before 15 years of age

## SHORT REPORT

# *Bordetella pertussis* seroprevalence in Belgian adults aged 20–39 years, 2012

K. HUYGEN<sup>1\*</sup>, C. RODEGHIERO<sup>1</sup>, D. GOVAERTS<sup>2</sup>, I. LEROUX-ROELS<sup>3</sup>,  
P. MELIN<sup>4</sup>, M. REYNDERS<sup>5</sup>, S. VAN DER MEEREN<sup>6</sup>,  
S. VAN DEN WIJNGAERT<sup>7</sup> AND D. PIERARD<sup>6</sup>

In the context of the Eupert-Labnet WP6 seroprevalence study (comparing sera from 14 European member states), 1500 **anonymized leftover** diagnostic samples were collected randomly during the second semester of 2012 by the laboratories of clinical biology of **six** participating **Belgian** centres, equally distributed between Flanders, Wallonia and Brussels Capital region. A total of 750 samples (125/ centre) were selected from subjects in the age group 20-29 years and 750 samples (125/ centre) from subjects in the age group 30-39 years.



Univ



Vrije Universiteit Brussel




# Conclusion of seroprevalence study

Sixty-one (4%) sera were indicative of an infection in the past two years (between 50 and 100 IU/ml) and another sixty-one (4%) sera had anti-PT IgG antibodies reflecting acute infection (> 100 IU/ml).

**These results highlight the presence of a *Bordetella pertussis* reservoir in the adult 'healthy' Belgian population**

# Laboratory diagnosis



# Only *Bordetella pertussis* is included in the ECDC diagnosis of pertussis

- ***Bordetella pertussis***

Exclusively isolated from humans, as agent of whooping cough (*has also been isolated from alveolar macrophages and blood*)

- ***Bordetella parapertussis***

Pertussis-like disease (no pertussis for ECDC)  
(mild cases: 20% pertussis, 40% aspecific bronchitis, 40% asymptomatic)

Also found in sheep

- ***Bordetella holmesii***

Rare cause of respiratory or not respiratory infections in humans, recently isolated from patients with pertussis-like disease

- ***Bordetella bronchiseptica***

Respiratory pathogen for and commensal of many animals, incl. dog, pig, cat & rabbit

Humans: rare cases of pertussis-like disease, opportunistic in immunodeficient patients



You are here: [Portal Home](#) > [English](#) > [Health Topics](#) > [Vaccine-preventable diseases](#) > [EUVAcnet](#) > [Case definitions](#) > [Pertussis](#)

## Vaccine-preventable diseases

News

Events

Publications

Surveillance reports

Public health developments

Scientific advances

Eurosurveillance articles

National plans

EU-IBD

EUVAcnet

Case definitions

Measles

Mumps

Rubella

Pertussis

Congenital rubella

## Pertussis

Pertussis (*Bordetella pertussis*)

The case definition and classification is that stipulated by [EU Commission Decision](#) of 8 August 2012.

### Clinical criteria:

Any person with a cough lasting at least two weeks and at least one of the following three:

- Paroxysms of coughing
- Inspiratory "whooping"
- Post-tussive vomiting

or

Any person diagnosed as pertussis by a physician

or

Apnoeic episodes in infants

### Laboratory criteria:

At least one of the following three:

- Isolation of *Bordetella pertussis* from a clinical specimen
- Detection of *Bordetella pertussis* nucleic acid in a clinical specimen
- *Bordetella pertussis* specific antibody response

Serology results need to be interpreted according to the vaccination status

### Epidemiological criteria:

# Structure NRC

## Two labs

### → UZ Brussel

- Diagnosis on respiratory samples (PCR; culture for strain typing)
- Most useful for young children
- Confirmation of diagnosis/strain identification for other labs

### → WIV-ISP

- Serological diagnosis (anti-PT IgG; not applicable if vaccine dosis < 1 year)
- Mostly samples from adults, generally one-point > 3 weeks symptoms

<b>GELIEVE DIT FORMULIER MET HET STAAL OP TE STUREN NAAR:</b>	
<b>PCR &amp; KWEEK en CONFIRMATIE &amp; TYPING VAN STAMMEN</b>	<b>ANTI-PERTUSSIS TOXINE ANTILICHAMEN</b>
Prof. Dr D. Pined UZ Brussel Microbiologie en Ziektenhygiëne Laarbeeklaan 101, 1090 Jette Tel.: 02477.50.00 E-mail: <a href="mailto:labmicro@uzbrussel.be">labmicro@uzbrussel.be</a>	Dr. Haygen Kris WIV - ISP Dienst Immunologie Engelendestraat 642, 1180 Brussels Tel.: 02573.33.76 ; Fax: 02573.33.67 E-mail: <a href="mailto:caroline.rodegiers@wiv-isp.be">caroline.rodegiers@wiv-isp.be</a>
<b>*GEGEVENS OVER HET LABORATORIUM DAT HET STAAL VERSTUURT:</b> Naam verantwoordelijke: ..... Naam laboratorium: ..... Dienst: ..... Adres: ..... Postcode/Woonplaats: ..... Tel.: ..... Fax: ..... E-mail adres: .....	<b>VOORBEHOUDEN VOOR HET REFERENTIELABORATORIUM</b>
<b>*PATIËNTGEGEVENS</b> Naam: ..... Geslacht: <input type="checkbox"/> M <input type="checkbox"/> V <input type="checkbox"/> onbekend Geboortedatum: ..... Postcode/Woonplaats: ..... Rijksoverheidsnummer: ..... Nationaliteit: ..... Recent verblijf in het buitenland: <input type="checkbox"/> ja <input type="checkbox"/> nee <input type="checkbox"/> onbekend Zo ja, land of straat: .....	<b>KLINISCHE GEGEVENS</b> Datum begin symptomen: ..... *Hoest: <input type="checkbox"/> ja <input type="checkbox"/> nee <input type="checkbox"/> onbekend Duur van de hoest: ..... weken ..... dagen Vergeseld door: Paroxysmale hoestbuien: <input type="checkbox"/> ja <input type="checkbox"/> nee Gierende inspiratie ("whooping"): <input type="checkbox"/> ja <input type="checkbox"/> nee Einken na het hoesten: <input type="checkbox"/> ja <input type="checkbox"/> nee Episodes van apnoe bij een zuigling: <input type="checkbox"/> ja <input type="checkbox"/> nee Zo ja, Geef details: ..... Asymptomatisch contact van een bevestigd geval: <input type="checkbox"/> ja <input type="checkbox"/> nee Zo ja, geef de referenties van dit geval: ..... Werd de patiënt gehospitaliseerd? <input type="checkbox"/> ja <input type="checkbox"/> nee Andere symptomen: ..... Outcome: <input type="checkbox"/> overleden datum overlijden: ..... <input type="checkbox"/> nog steeds ziek <input type="checkbox"/> genezen <input type="checkbox"/> onbekend
<b>*GEGEVENS OVER HET STAAL</b> Respiratoire monster (naar UZ Brussel te verzenden) Identificatienummer: ..... Datum afname: ..... Type monster: <input type="checkbox"/> nasofaryngeaal aspiraat <input type="checkbox"/> nasofaryngeaal spoeling <input type="checkbox"/> nasofaryngeaal lavage <input type="checkbox"/> nasofaryngeaal uitstrijk <input type="checkbox"/> anders (algemeen), precieser: .....	<b>*VACCINATIE GESCHIEDENIS</b> Werd de patiënt ooit gevaccineerd: <input type="checkbox"/> ja <input type="checkbox"/> nee <input type="checkbox"/> onbekend Zo ja, hoeveel doses heeft hij gekregen: ..... datum laatste dosis: .....
Stam (naar UZ Brussel te verzenden) Identificatienummer: ..... Datum isolatie: ..... Gefoelend uit: ..... Serum (naar WIV Engelendestraat te verzenden) Identificatienummer: ..... Datum afname: ..... Werd er reeds een eerste serumstaal onderzocht <input type="checkbox"/> ja <input type="checkbox"/> nee Zo ja: Referentie: ..... Datum: .....	Naam + voornaam van de aanvragende geneesheer: ..... Stempel van de aanvragende geneesheer: .....

\*Verplicht in te vullen

# NRC pertussis

Most important data

- Duration of symptoms
- Vaccination

# Real-time PCR: which target for which species?

- Screening assay: IS481-IS1001
  - High sensitivity: high copy number
  - Low specificity
- Confirmation assay: IS1002-recA
  - Lower sensitivity
  - Specificity is high in combination with first assay
- At first other assays were only performed after positive result in screening
  - practical difficulties
  - performing both at the same time

	B. pertussis	B. parapertussis	B. holmesii	B. bronchiseptica
IS481	+++	-	++	+/-
IS1001	-	++	-	+/-
IS1002	+	+	-	+/-
recA	-	-	+	-


# PCR interpretation

- Sensitivity

- IS481: 3 CFU/PCR
- IS1001: 5 CFU/PCR
- recA: 52 CFU/PCR
- IS1002: +/- 40 CFU/PCR

- Possible outcomes:

- Positive for *B. pertussis*
- Positive for *B. parapertussis*
- Positive for *B. holmesii*
- Positive for *B. species*, probably *B. pertussis* if compatible with clinical information
- Positive for *B. species*, probably *B. parapertussis* if compatible with clinical information
- undetermined (weak positive signal, which was not confirmed by repeating the test, sample should be considered as negative)





# Results 2014


- **1395** cases of *B. pertussis* infection

- Serology: **930** cases
- PCR: **456** cases
- Serology + PCR: **7** cases
- **2** strains for confirmation by culture

- **94** *B. parapertussis*
- **7** *B. holmesii*




# *B. pertussis* cases reported by the NRC




© WIV-ISP | Data source: NRC


# Total number of reported pertussis cases by semester by surveillance system, 2005-2015 (first semester), Belgium.



The incidence of the reported pertussis cases by the NRC per region per 100,000, 2014, Belgium (based on 2014 Belgian population data).



# Geographical distribution of reported pertussis cases by borough, 2014, Belgium (NRC, the sentinel laboratory network and the mandatory notification).



## Deaths due to *Bordetella* (*pertussis*) per age group, 2000-2012, Belgium.

	Mortality data (all <i>Bordetella</i> infections)		Minimal Clinical Dataset ( <i>Bordetella pertussis</i> infections)	
	Number of recorded deaths	Age group (in years)	Number of recorded deaths	Age group (in years)
2000	1	<1	<5	65-74
2001	0	/	0	/
2002	0	/	0	/
2003	0	/	0	/
2004	1	<1	<5	<1
2005	1	<1	<5	45-64
2006	1	<1	0	/
2007	0	/	0	/
2008	0	/	<5	15-19
2009	1	<1	<5	<1
2010	1	<1	<5	<1
2011	2	<1	<5	<1
2012	1	<1	<5	<1

Ann. Inst. Pasteur Vol 20, 731-741 1906

# LE MICROBE DE LA COQUELUCHE

PAR LES D<sup>rs</sup> J. BORDET ET O. GENGOU

Avec la planche XXVIII.

(Travail de l'Institut Pasteur de Bruxelles.)

